In a significant move to fortify the domestic supply chain for critical diagnostic tools, Italian imaging giant Bracco Imaging has announced a $230 million investment to establish its first-ever sterile manufacturing facility on US soil. Located in Sanford, Lee County, North Carolina, the facility represents a pivotal shift in the company’s global operational strategy, designed to mitigate the risks of international logistics and meet the surging demand for high-quality injectable contrast media.
The project is expected to generate 200 high-skilled jobs in the region, marking a major milestone for both Bracco and the state of North Carolina. As the global medical imaging landscape continues to evolve, the necessity for robust, locally produced diagnostic agents has never been more apparent.
Main Facts: The Sanford Manufacturing Initiative
Bracco Imaging, a privately-owned leader in diagnostic imaging, is embarking on a comprehensive expansion that will see the construction of a state-of-the-art sterile manufacturing plant. This facility is tasked with producing the company’s flagship injectable contrast media—agents essential for X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and contrast-enhanced ultrasound (CEUS) procedures.
The choice of Sanford, North Carolina, was deliberate. The region has become a burgeoning hub for life sciences and advanced manufacturing, offering the necessary infrastructure and talent pool to support complex pharmaceutical operations. The $230 million capital expenditure covers the construction of the facility, the installation of high-precision sterile filling equipment, and the implementation of advanced quality control systems.
Beyond the immediate economic impact of 200 new jobs, the facility is designed to optimize the supply chain. By localizing production, Bracco aims to significantly reduce the lead times associated with transatlantic shipping, lower transportation costs, and provide American healthcare providers with a more reliable, consistent stream of diagnostic agents.
Chronology: From Strategic Planning to Implementation
The journey to the Sanford site was the result of long-term strategic analysis. While the announcement was finalized in late 2026, the groundwork for this expansion was laid years prior as the company observed increasing volatility in global shipping and geopolitical landscapes.
- 2024-2025: Bracco executives conducted a feasibility study to evaluate the benefits of domestic manufacturing in the US, prompted by rising global demand and a desire to hedge against supply chain disruptions.
- March 2025: Broader trends in US manufacturing were catalyzed by the Trump Administration’s focus on increasing domestic manufacturing footprints, influencing industry-wide investments.
- October 27, 2026: The State of North Carolina’s Economic Investment Committee officially approved a Job Development Investment Grant (JDIG) for Bracco’s US division, signaling the formal green light for the project.
- Late 2026 and Beyond: The project has moved into the engineering and construction phase, with the site anticipated to begin operational ramp-up in the coming years.
This timeline highlights the company’s proactive stance. Rather than reacting to localized shortages, Bracco has strategically positioned itself to lead the market in supply chain security.
Supporting Data: The Expanding Market for Contrast Media
The diagnostic imaging market is undergoing a period of robust expansion. According to GlobalData, the broader diagnostic imaging sector is growing at a compound annual growth rate (CAGR) of 4.5%. The market is projected to reach a staggering $87.6 billion in 2035, a significant climb from its $56.4 billion valuation in 2025.
Within this, the demand for contrast media—the "dyes" that allow clinicians to visualize blood vessels, soft tissues, and organ function—is tracking upward. GlobalData models indicate that the combined market for X-ray/CT, MRI, and ultrasound contrast media is set to reach approximately $7.4 billion by 2035.
Market Drivers:
- Aging Populations: As the global population ages, the prevalence of conditions requiring diagnostic imaging (such as cardiovascular disease and oncology) increases.
- Precision Medicine: The rise of minimally invasive diagnostic procedures relies heavily on high-definition imaging, which is only possible through the use of contrast agents.
- Technological Advancements: Newer, more sensitive ultrasound and MRI machines require specialized contrast agents, driving innovation and demand for Bracco’s product portfolio.
The data suggests that Bracco’s investment is not merely a defensive measure against supply chain instability but an aggressive capture of a growing market share.
Official Responses and Strategic Vision
The investment has been met with strong support from both the company’s leadership and local government officials.
Fulvio Renoldi Bracco, Vice Chairman and CEO of Bracco Imaging, stated:
"The US is our largest market and home to many of the patients we serve. Producing injectable contrast media here in Sanford brings our supply closer to American hospitals and patients and makes it even more resilient."
This statement underscores the company’s "proximity to the patient" philosophy. By eliminating the distance between the factory floor and the hospital bed, Bracco is minimizing the potential for shortages that could otherwise delay critical patient diagnoses.
North Carolina Governor Josh Stein expressed his enthusiasm for the project:
"North Carolina’s longstanding strengths in manufacturing, innovation, and workforce development have created an ecosystem that gives companies like Bracco the confidence to invest here."
The state’s partnership, manifested through the JDIG grant, is a testament to the symbiotic relationship between private industry and regional economic development. The grant authorizes a potential reimbursement of up to $2.86 million over 12 years, contingent upon the project’s performance, which is estimated to inject $1.78 billion into the state’s economy over that same period.
Implications: A New Era for Medtech Supply Chain Resilience
The Bracco expansion does not exist in a vacuum; it is part of a broader, systemic trend in the medical device and pharmaceutical sectors. In recent years, geopolitical volatility—such as the 2026 closure of the Strait of Hormuz and general global trade friction—has exposed the vulnerabilities of "just-in-time" global supply chains.
Shifting Geopolitics and Domestic Manufacturing
The healthcare industry is witnessing a "re-shoring" or "near-shoring" movement. Major players are increasingly looking to move manufacturing back to the US to protect against sudden geopolitical shocks.
- Comparison to J&J: In June 2025, Johnson & Johnson committed $1 billion to bolster its contact lens manufacturing in Florida, part of a larger $55 billion commitment to increase the company’s US manufacturing footprint.
- The Regulatory Environment: While pharma-related incentives have historically driven these shifts, the medtech industry is beginning to follow suit. The Bracco case serves as a benchmark for how specialized imaging companies can leverage similar economic incentives to ensure that the "backbone" of modern diagnostic medicine remains secure.
Impact on Healthcare Providers
For hospitals and diagnostic centers, this development is largely positive. The most immediate implication is the reduction of "supply chain anxiety." When hospitals can rely on domestic production, they can maintain lower inventory levels without the fear of sudden stockouts, which in the past have led to the cancellation or postponement of essential diagnostic imaging procedures.
Furthermore, a local manufacturing footprint allows for faster collaboration between the manufacturer and the clinician. As Bracco continues to innovate in the fields of CNS imaging and contrast-enhanced ultrasound, having a localized manufacturing team will allow for more rapid testing, production, and distribution of new-generation agents.
The Road Ahead
The success of the Sanford facility will likely serve as a litmus test for other European medtech companies considering similar moves. If Bracco can successfully navigate the regulatory environment and integrate its North Carolina facility into its global network while maintaining its high standards for sterile production, it will provide a roadmap for others to follow.
In summary, the $230 million investment is more than a new building in North Carolina. It is a strategic hedge against a volatile world, a commitment to American patients, and a clear signal that the future of medical imaging relies on the reliability of the supply chain just as much as it does on the sophistication of the technology itself. As the market for diagnostic imaging grows toward that $7.4 billion milestone by 2035, Bracco Imaging is positioning itself to be at the center of the American diagnostic experience.
About the Author
